Table 1 Baseline characteristics
From: Mechanical effects of left ventricular midwall fibrosis in non-ischemic cardiomyopathy
No MWF | MWF | P | |
|---|---|---|---|
N | 84 | 32 | |
Age, yrs | 62.3 ± 13.7 | 63.8 ± 11.9 | 0.29 |
Male, n (%) | 51 (61) | 27 (84) | 0.02 |
Height, m | 1.68 ± 0.09 | 1.74 ± 0.09 | 0.02 |
Weight, Kg | 83.4 ± 18.6 | 83.3 ± 12.6 | 0.97 |
NYHA class | 0.20 | ||
I | 4 (5) | 3 (9) | |
II | 15 (18) | 8 (25) | |
III | 47 (56) | 11 (34) | |
IV | 9 (11) | 5 (16) | |
Unknown | 9 (11) | 5 (16) | |
Diabetes mellitus, n (%) | 13 (16) | 7 (24) | 0.42 |
Hypertension, n (%) | 18 (22) | 5 (17) | 0.61 |
Atrial fibrillation, n (%) | 15 (18) | 8 (24) | 0.44 |
Medication, n (%) | |||
Loop diuretics | 62 (81) | 26 (89) | 0.47 |
ACE-I or ARB | 77 (97) | 27 (90) | 0.31 |
Beta-blockers | 51 (65) | 20 (66) | 1.00 |
Aldosterone antagonists | 36 (46) | 10 (35) | 0.29 |
Systolic blood pressure, mmHg | 124.3 ± 20.5 | 119.6 ± 23.1 | 0.38 |
Diastolic blood pressure, mmHg | 71.5 ± 11.9 | 71.7 ± 13.8 | 0.96 |
QRS duration (ms) | 144 (28) | 149 (32) | 0.48 |